| Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients. | |
| | |
MedLine Citation:
|
PMID: 15205265 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
An active assessment of the host capacity to prevent infection during myelosuppression should be beneficial in patients receiving high-dose chemotherapy. A single dose of granulocyte colony-stimulating factor (G-CSF) (5 microg/kg) was given to 57 patients with multiple myeloma early after the completion of 85 high-dose chemotherapy (melphalan 200 mg/m2) courses. This provoked a highly variable white blood cell (WBC) peak after 12 to 14 hours. The median WBC count was 21,000/microL (range, 6400-60,600/microL) after a first high-dose therapy (n = 50) and 13,500/microL (range, 4700-24,800/microL) after a second high-dose therapy (n = 35). The responsiveness to single G-CSF was associated with the risk of infection during subsequent cytopenia (P =.003). This association was significant after adjustment for neutropenia duration. Notably, the result of testing G-CSF responsiveness was opportunely available before the onset of leukopenia, and G-CSF responsiveness was more informative than neutropenia duration regarding the risk of infection. Furthermore, there was an association between the responsiveness to G-CSF and stem cell engraftment (P <.005), which remained significant after adjustment for the number of transplanted CD34+ cells. Our results show for the first time that G-CSF potentially could be used for an early in vivo assessment of defense to infection in recipients of high-dose chemotherapy. |
| | |
Authors:
|
Christian Straka; Fuat Oduncu; Axel Hinke; Hermann Einsele; Evi Drexler; Brigitte Schnabel; Lubomir Arseniev; Jochem Walther; August König; Bertold Emmerich |
Related Documents
:
|
12088975 - Small-dose dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy... 7875025 - Comparison of different schedules of ondansetron (gr 38032f) administration during cisp... 8761585 - Relapses following treatment of early-stage trypanosoma brucei gambiense sleeping sickn... 8349185 - Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutr... 22456295 - No clinically relevant drug-drug interactions when dalcetrapib is co-administered with ... 12200985 - A comparison of high versus low dose recombinant human erythropoietin versus blood tran... |
Publication Detail:
|
Type: Journal Article Date: 2004-06-17 |
Journal Detail:
|
Title: Blood Volume: 104 ISSN: 0006-4971 ISO Abbreviation: Blood Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-20 Completed Date: 2004-11-04 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7603509 Medline TA: Blood Country: United States |
Other Details:
|
Languages: eng Pagination: 1989-94 Citation Subset: AIM; IM |
Affiliation:
|
Medizinische Klinik-Innenstadt, Klinikum der Universität München, München, Germany. christian.straka@med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antigens, CD34 / chemistry Antineoplastic Agents / adverse effects* Blood Transfusion Clinical Trials as Topic Female Granulocyte Colony-Stimulating Factor / therapeutic use* Hematopoietic Stem Cells / cytology Humans Leukocyte Count Leukocytes / cytology, drug effects Leukopenia / prevention & control* Male Middle Aged Multiple Myeloma / drug therapy* Neoplasms / drug therapy* Prognosis Risk Stem Cells / cytology Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD34; 0/Antineoplastic Agents; 143011-72-7/Granulocyte Colony-Stimulating Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses.
Next Document: Unusual immunophenotype of CD8+ T cells in familial hemophagocytic lymphohistiocytosis.